Gluten in Medicine Disclosure Act of 2019

Bill: 116-s-3021
Sponsor: full_name: Sen. Blumenthal, Richard [D-CT]
Introduced: 2019-12-11
Policy area: Health
Subjects: Consumer affairs

Drug safety, medical device, and laboratory regulation

Grain

Nutrition and diet

Prescription drugs
Latest action: action_date: 2019-12-11
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2019-12-11
action_desc: Introduced in Senate
text: <p><b>Gluten in Medicine Disclosure Act of 2019</b></p> <p>This bill prohibits the sale of any drug intended for human use that contains an ingredient derived from a gluten-containing grain unless the drug's label (1)states that the drug contains such an ingredient, and (2)identifies the type of grain from which the ingredient is derived.</p>

tv_txt: II 116th CONGRESS 1st Session S. 3021 IN THE SENATE OF THE UNITED STATES December 11, 2019 Mr. Blumenthal introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug that is intended for human use and contains an ingredient that is derived directly or indirectly from a gluten-containing grain to identify each such ingredient, and for other purposes.

1. Short title This Act may be cited as the Gluten in Medicine Disclosure Act of 2019 . 2. Labeling of drugs with an ingredient made from a gluten-containing grain (a) Misbranding Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following: (ee) If it is a drug— (1) that is intended for human use; (2) that contains an ingredient that is derived directly or indirectly from a gluten-containing grain (including wheat, barley, rye, and crossbred hybrids of such grains); and (3) whose label fails— (A) to state that the drug contains such an ingredient; and (B) to identify each such ingredient and the type of gluten-containing grain from which it is derived. . (b) Applicability Section 502(ee) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a) of this section, shall apply beginning on the earlier of— (1) a date to be determined by the Secretary of Health and Human Services; and (2) the date that is 2 years after the date of the enactment of this Act.